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ABSTRACT Although specific proteinases play a critical
role in the active phase of apoptosis, their substrates are
largely unknown. We. previously identified poly(ADP-ribose)
polymerase (PARP) as an apoptosis-associated substrate for
proteinase(s) related to interleukin 1p8-converting enzyme
(ICE). Now we have used a cell-free system to characterize
proteinase(s) that cleave the nuclear lamins during apoptosis.
Lamin cleavage during apoptosis requires the action of a
second ICE-like enzyme, which exhibits kinetics of cleavage
and a profile of sensitivity to specific inhibitors that is distinct
from the PARP proteinase. Thus, multiple ICE-like enzymes
are required for apoptotic events in these cell-free extracts.
Inhibition of the lamin proteinase with tosyllysine "chloro-
methyl ketone" blocks nuclear apoptosis prior to the packag-
ing ofcondensed chromatin into apoptotic bodies. Under these
conditions, the nuclear DNA is fully cleaved to a nucleosomal
ladder. Our studies reveal that the lamin proteinase and the
fragmentation nuclease function in independent parallel
pathways during the final stages of apoptotic execution.
Neither pathway alone is sufficient for completion of nuclear
apoptosis. Instead, the various activities cooperate to drive the
disassembly of the nucleus.
Proteinases of the interleukin 1(3-converting enzyme (ICE)!
ced-3 family are essential for the execution of apoptotic cell
death (1). These proteinases can induce apoptotic death when
overexpressed in cultured mammalian (2-5) or insect (6) cells.
Inhibition of ICE family enzymes by CrmA blocks apoptosis
induced by factor withdrawal (7) or by the Fas and tumor
necrosis factor (TNF) pathways (8). Although gene knockout
experiments have revealed that ICE itself is not essential for
many types of apoptotic death (9, 10), it does appear to be
required for Fas-mediated cell death (10). In addition, the
demonstration that apoptosis can be induced by introduction
of trypsin, chymotrypsin, or proteinase K into cells (11) raises
questions about the interpretation of experiments in which
ICE family members are overexpressed in transfected cells.
Additional studies using complementary approaches are
therefore needed to clarify the role of ICE-like proteinases in
apoptosis.
Studies using a cell-free system in which endogenous enzy-
matic activities drive apoptotic events have provided indepen-
dent biochemical evidence for the involvement of an ICE-like
proteinase in apoptotic cell death (12). This cell-free system
uses concentrated extracts from chicken DU249 cells in the
condemned (committed) phase of apoptosis (13) to induce a
synchronous cascade of apoptotic events in isolated nuclei (14,
15). The DU249 cells become committed to apoptosis as a
result of an S-phase aphidocolin block and are subsequently
collected in M phase; hence, the extracts are referred to as S/M
extracts. In these extracts, as in apoptotic cells (16), the nuclear
enzyme poly(ADP-ribose) polymerase (PARP) is rapidly and
selectively cleaved (12). The PARP proteinase does not cleave
pro-interleukin-1,, but otherwise resembles ICE in several
respects: it cleaves PARP at the sequence Glu-Val-Asp I Gly,
which is similar to a sequence in pro-interleukin-1l3 that is
cleaved by ICE; and it is selectively inhibited by Tyr-Val-Ala-
Asp-CH2Cl [YVAD "chloromethyl ketone" (YVAD-cmk)], a
highly specific inhibitor of ICE family proteinases. These
similarities led us to designate the PARP proteinase prICE
(proteinase resembling ICE). In further experiments, treat-
ment with YVAD-cmk at concentrations that inhibit prICE
abolished all hallmark events of apoptosis in the S/M extracts
(12), suggesting that prICE plays a pivotal role in initiating the
apoptotic cascade. It now appears that prICE activity is the
summation of the activities of multiple ICE family members
acting in concert (results described below). We therefore
propose to use the term prICE to refer to the constellation of
ICE-like proteinases that are active in S/M extracts. Thus,
prICE activity might include contributions from Nedd-2
(Ich-1) (3, 4), CPP32 (Yama) (6, 17), TX (5), and other
yet-to-be-described ICE family members.
In the present study we have used our cell-free system to
characterize the specific cleavage of the nuclear lamins during
apoptosis. We and others (15, 18) have previously shown that
apoptosis in intact cells is accompanied by disassembly of the
nuclear lamina. This intermediate filament meshwork is be-
lieved to play a role in nuclear envelope integrity and the
organization of interphase chromatin (19). Lamina disassem-
bly during apoptosis is accompanied by proteolytic cleavage of
the lamins (18, 20). Using the cell-free system, we now show
that all three nuclear lamins are cleaved, that lamin cleavage
involves the action of an ICE-like proteinase distinct from the
PARP proteinase, and that lamin cleavage is required for
packaging of the condensed chromatin into apoptotic bodies.
MATERIALS AND METHODS
Reagents. YVAD-cmk (Bachem) and Ala-Ala-Pro-Phe-
CH2Cl [AAPF "chloromethyl ketone" (AAPF-cmk)] (En-
Abbreviations: ICE, interleukin 13-converting enzyme; PARP, poly-
(ADP-ribose) polymerase; S/M extract, extract from cells committed
to apoptosis by an S-phase aphidocolin block and subsequently
collected in M phase; DMSO, dimethyl sulfoxide; PMSF, phenyl-
methylsulfonyl fluoride; AAPF-cmk, Ala-Ala-Pro-Phe-CH2Cl
(AAPF "chloromethyl ketone"); YVAD-cmk, Try-Val-Ala-Asp-
CH2Cl; TPCK, Tos-Phe-CH2Cl; TLCK, Tos-Lys-CH2Cl.
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zyme Systems Products Livermore, CA) were dissolved as 18.3
mM and 50 mM stock solutions, respectively, in dimethyl
sulfoxide (DMSO). Other chemicals were obtained from
Sigma and dissolved as follows: phenylmethylsulfonyl fluoride
(PMSF), 50 mg/ml (0.29 M) in methanol; 3,4-dichloroisocou-
marin, 5 mg/ml in DMSO; aprotinin, chymostatin, leupeptin,
antipain, and pepstatin, 10 mg/ml in DMSO; Tos-Lys-CH2Cl
[tosyl-L-lysyl "chloromethyl ketone" (TLCK)] and Tos-Phe-
CH2Cl [tosyl-L-phenylalanyl "chloromethyl ketone" (TPCK)],
20mM in methanol; E-64, 1 mg/ml (2.8 mM) in 10 mM Hepes
(pH 7.0).
The following antibodies were used for immunoblotting of
PARP and lamins as described (15): C-2-10 monoclonal anti-
body against PARP (16), an affinity-purified rabbit antibody
raised against the carboxyl terminus of lamin A (gift of Brian
Burke, University of Calgary), a goat antiserum that recog-
nizes lamins Bi and B2 (gift of Larry Gerace, Scripps Research
Foundation, La Jolla, CA), and a rabbit antiserum recognizing
lamins A and C (gift of Mervyn Monteiro, University of
Maryland). Antibodies were detected with 1251-protein A and
autoradiography or by ECL (Amersham). In some cases, blots
were reprobed with different antibodies after stripping in 60
mM Tris/100 mM 2-mercaptoethanol/2% SDS, pH 6.7.
In Vitro Apoptotic Reaction, Analysis of DNA Fragmenta-
tion, and Detection of the Cleavage ofPARP and Lamins. S/M
extracts, real mitotic extracts, and interphase extracts were
prepared from DU249 cells as described (14, 15). Nuclei
isolated from HeLa cells were added to these extracts and
analyzed for morphologic changes, DNA fragmentation, and
protein cleavage as described (12, 15).
Stock solutions of inhibitors were diluted with MDB buffer
(15) and added tQ aliquots of S/M extract. Control aliquots
were supplemented with DMSO or methanol to control for
solvent effects. After a 15-min preincubation at 37°C, HeLa
nuclei or purified PARP and lamins were added, incubated for
1 hr at 37°C, and then subjected to SDS/PAGE and immu-
noblotting.
Induction of Apoptosis in Cultured Cells. A549 human lung
cancer cells (kindly provided by Robert Casero, Johns Hopkins
Oncology Center) were cultured in RPMI 1640 medium
containing 5% fetal bovine serum penicillin G at 50 units/ml,
streptomycin at 50 ,ug/ml, and 2mM glutamine. Subconfluent
cells were incubated for 48 hr with 20 ,M topotecan (20).
Apoptotic cells were recovered from the -culture supematant
by sedimentation at 200 x g for 10 min and washed once in
serum-free medium, and extracts were prepared for SDS/
PAGE (20).
Indirect Immunofluorescence of Nuclear Lamins. HeLa
nuclei adsorbed to Adhesioslides (Marienfeld, Bad Mergen-
theim, Germany) were incubated with S/M extracts in the
absence or presence of TLCK (100 ,uM) for 1 hr at 37°C. They
were then fixed and stained with 4',6-diamidino-2-phenylin-
dole or antibody against the carboxyl terminus of human lamin
A as described (16).
Expression and Purification of Recombinant Human
Lamins. The human lamin A cDNA (21) was subcloned into
the pET3a vector (22). A sequence coding for the 12-amino
acid Myc tag 9E10 (23) was inserted by site-directed mutagen-
esis at the amino terminus prior to subcloning. This construct
was expressed in Escherichia coli strain BL21(DE3)/pLysE
and protein was purified from inclusion bodies as described
(24). Inclusion-body preparations were dissolved in 8 M
urea/25 mM Hepes, pH 8/1 mM EDTA/1 mM dithiothreitol
and the protein was further purified on the Mono S column of
the Pharmacia FPLC system using a 0-1 M NaCl gradient (24).
Before use, the recombinant lamins were dialyzed against 20
mM Tris HCl, pH 8.8/500 mM KCl (150 mM for lamin B)/2
mM EDTA/1 mM dithiothreitol/0.2% Triton X-100.
The human lamin Bi cDNA (25) was subcloned into the
pETl5b vector so that the lamin Bi was expressed as a fusion
protein with the 20-amino acid histidine tag at the amino
terminus (Novagen). The expressed protein was purified with
the Ni2+ chelation resin (Novagen). The protein eluted from
the Ni2+ column was concentrated by precipitation with
ammonium sulfate at 50% saturation and then dialyzed against
6 M urea/25 mM Tris/1 mM EDTA/2 mM dithiothreitol. The
protein was further purified on a Pharmacia Mono Q column
with a 0-1 M NaCl gradient.
RESULTS
Cleavage of lamins A, B, and C, a feature of apoptosis in a
variety of cell types (18, 20, 26), occurred following addition of
HeLa nuclei to S/M extracts (Fig. 1). In control experiments,
real mitotic extracts (RME, Fig. 1) or interphase extracts (data
not shown) failed to cleave the lamins or induce apoptotic
changes in added nuclei (15). Lamin cleavage appears to occur
at the same site in the cell-free system and in cells undergoing
apoptosis. Cleavage of lamin A resulted in appearance of an
-45-kDa fragment that reacted with an antibody against the
carboxyl terminus of the polypeptide (Fig. 1 A and B, lane 2).
A significant portion of this fragment was released from nuclei
in soluble form (Fig. 1A, lanes S). Cleavage of lamin A in the
A549 human lung cancer cell line undergoing apoptosis fol-
lowing exposure to etoposide produced a fragment of identical
mobility (Fig. 1B, lane 4). Equivalent results were also ob-
tained with the MDA-MB-468 breast cancer cell line (data not
shown).
To determine whether the lamin proteinase and the previ-
ously described PARP proteinase were identical, we compared
several properties of these enzyme activities. In contrast to
cleavage ofPARP, which is completed within 3 min of addition
of nuclei to the extracts (12), lamin cleavage was slower, being
noticeable at 15 min and requiring 30-45 min for completion.
Moreover, the extent of lamin cleavage was inversely corre-
lated with the number of nuclei added per microliter of extract.
When large numbers of nuclei were used, a portion of the
lamins remained uncleaved even after a 60-min incubation
(Fig. 1B, lane 2). These results suggested that the lamin
proteinase might be different from the PARP proteinase.
Studies using a panel of proteinase inhibitors provided
additional evidence that the lamin and PARP proteinases are
distinct enzymatic activities. YVAD-cmk inhibited both lamin
and PARP cleavage, but the former was much more sensitive
to the drug. Under the conditions employed (2 x 105 nuclei per
,ul of extract), 1 or 10 ,uM YVAD-cmk inhibited PARP
cleavage by -50% (Fig. 2, lanes 4b and 4c). In contrast,
cleavage of lamins A and B was completely abolished by 1 ,uM
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FIG. 1. S/M extracts cleave lamins in isolated nuclei at a site
indistinguishable from that cleaved during apoptosis in cultured cells.
(A) Nuclei isolated from HeLa cells (2.2 x 106) were incubated in 20
,1 of real mitotic extract (RME) (Left) or apoptotic (S/M) extract
(Right) for the indicated time at 37°C. After separation of the insoluble
nuclear fraction (pellet, P) from the soluble fraction (supernatant, S)
by centrifugation at 10,000 x g for 3 min, samples were subjected to
SDS/10% PAGE and immunoblotting with antibody against the
carboxyl terminus of lamin A (Upper) or an antiserum against lamins
Bi and B2 (Lower). (B) HeLa nuclei incubated in buffer (lane 1) or
S/M extract (lane 2) were electrophoresed in the same gel as whole cell
extracts prepared from A549 human lung cancer cells before (lane 3)
or after (lane 4) induction of apoptosis with topotecan.
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FIG. 2. The PARP and lamin proteinases show a different pattern of sensitivity to proteinase inhibitors. After a 15-min preincubation of S/M
extract with inhibitors at 37°C, HeLa nuclei were added (200,000 per ,Al), incubated for 1 hr at 37°C, and then subjected to SDS/PAGE and
immunoblotting. Lanes 1 and 6, nuclei incubated in buffer alone; lanes 2-4, Preincubation of S/M extract with buffer (lane 2), with 1% DMSO
(lane 3), or with 0.1, 1.0, 10, or 100 ,uM YVAD-cmk (lanes 4a-4d, respectively); lane 5, S/M extract alone (no nuclei added); lanes 7-13,
preincubation of S/M extract with 0.5% methanol (lane 7), 1 mM PMSF (lane 8), 100 ,uM TLCK (lane 9), 100 ALM TPCK (lane 10), 100 ILM
YVAD-cmk (lane 11), 10 ,LM E-64 (lane 12), or 10 mM EDTA (lane 13). After detection of lamin B with 125I-protein A (Bottom) the same blot
was then probed for PARP with monoclonal antibody C-2-10 by ECL (Top), stripped of anti-PARP antibody, and probed for lamin A by ECL
(Middle).
YVAD-cmk (lane 4b), suggesting that the lamin proteinase
might be a second ICE-like proteinase with a higher affinity for
YVAD-cmk than the PARP proteinase. In addition, cleavage
of lamin A (Fig. 2 Middle) and lamin B (Fig. 2 Bottom) was
abolished by TLCK (lane 9), an inhibitor that had no effect on
PARP cleavage (Fig. 2 Top). A number of other proteinase
inhibitors including PMSF (1 mM), TPCK (100 ,uM), E-64 (10
,uM), EDTA (10 mM), aprotinin (0.097 trypsin inhibitor
unit/ml), chymostatin (20 ,ug/ml), leupeptin (20 ,ug/ml),
antipain (20 ,.g/ml), pepstatin (10 ,ug/ml), 3,4-dichloroiso-
coumarin (10 ,ug/ml), EGTA (10 mM), and AAPF-cmk (100
,uM) had no effect on the cleavage of nuclear lamins or PARP
in S/M extract (Fig. 2 and data not shown).
The observation that TLCK inhibits lamin, but not PARP,
cleavage allowed us to assess the role of the lamin proteinase
in the pathway of apoptotic execution. Nuclei added to S/M
extracts ordinarily undergo a sequential series of structural
changes that starts with condensation and collapse of the
chromatin against the nuclear envelope, proceeds with sepa-
ration of this rim of condensed chromatin into discrete regions,
and concludes with packaging of these regions into compact
apoptotic bodies that ultimately bud through the nuclear
membrane (15). YVAD-cmk prevents all of these morpholog-
ical changes (12). In contrast, addition of TLCK to the extracts
resulted in arrest after the first stage, with the condensed
chromatin forming a continuous rim around the nuclear
periphery (Fig. 3A). This arrest was specific for TLCK and was
not observed when extracts were treated with PMSF, 3,4-
dichloroisocoumarin, aprotinin, chymostatin, leupeptin, anti-
pain, pepstatin, TPCK, E-64, EGTA, or AAPF-cmk (data not
shown). Interestingly, treatment with TLCK did not prevent
the cleavage of DNA into oligonucleosomal fragments (Fig.
3C).
To determine whether the lamin proteinase is a soluble
component in S/M extracts or an endogenous nuclear protein
that is activated by an extract component, we examined the
ability of S/M extracts to cleave purified recombinant lamins.
Purified cloned human lamin A underwent some proteolysis in
E. coli, and appeared on immunoblots as a series of bands (Fig.
4, lane 3). The major recombinant lamin A species migrated
slightly more slowly than mature lamin A in HeLa nuclei (Fig.
4, lanes 8c and 9), possibly as a result of the presence of a Myc
tag and the absence of carboxyl-terminal processing of the
recombinant protein (27).
Incubation of recombinant lamin A in S/M extracts resulted
in cleavage, yielding a major immunoreactive fragment of -52
kDa (Fig. 4, lane 5). No cleavage was seen when recombinant
lamin A was incubated in control, interphase extract (Fig. 4,
lane 4). Although the fragments differ slightly in their mobility
in SDS/PAGE from those seen with intact nuclei, the differ-
ences in mobility between the full-length and cleaved forms are
consistent with those expected if the recombinant and native
lamins are cleaved at the same site.
The cleavage of recombinant lamin A was abolished by
addition of 1 ,M YVAD-cmk to S/M extracts (Fig. 4, lane 8a),
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FIG. 3. Inhibition of the lamin proteinase blocks the packaging of
condensed chromatin into apoptotic bodies but does not affect inter-
nucleosomal DNA cleavage. (A) HeLa nuclei were stained with
4',6-diamidino-2-phenylindole to reveal the intranuclear distribution
of DNA (Left) and with anti-lamin A (Right). (B and C) HeLa nuclei
(50,000 per gl) were incubated with S/M extract supplemented either
with TLCK (100 ,M) or MDB buffer. (B) Half of each sample was
analyzed by immunoblotting with an antibody recognizing lamins A
and C. (C) DNA isolated from the other half of the sample was
subjected to electrophoresis in a 1% agarose gel and detected as
described (15).
Proc. Natl. Acad. Sci. USA 92 (1995)
n^ n it-1cb I
Proc. Natl. Acad. Sci. USA 92 (1995) 9045
Extract HeLa
alone pure PARP + recomb. lamin A nuclei
S/M extract m m
Control extract
Buffer 'm
1 2 3 4 5 6 7 8a 8b 8c 9 10 kDa
PARP
_ 116
PARP 95
fragment
68lamin A
60
laminA 43
fragment
40
FIG. 4. Purified recombinant lamin A is cleaved in S/M extracts.
Lane 1, control interphase extract alone; lane 2, S/M extract alone;
lanes 3 and 4: purified PARP (40 ng/,ll) and lamin A (40 ng/,ul) in
buffer (lane 3) or control interphase extract (lane 4); lanes 5-8,
purified PARP and lamin A in S/M extract pretreated with 0.5%
methanol (lane 5), 100 ,uM TLCK (lane 6), 100 ,uM TPCK (lane 7),
or 1, 10, or 100 ,uM YVAD-cmk (lanes 8a-8c, respectively); lane 9,
HeLa nuclei in buffer; lane 10, HeLa nuclei in S/M extract. S/M
extracts were pretreated with proteinase inhibitors for 15 min at 37°C.
After a further 60 min, the samples were subjected to SDS/PAGE and
immunoblotting. Sequential detection of PARP and lamin A by ECL
was as described in the legend to Fig. 2.
about 10 times less YVAD-cmk than was required to block
PARP cleavage (Fig. 4, lanes 8a-c, compare Upper and Lower).
However, cleavage of recombinant lamin A in S/M extracts
was inhibited only -50% by TLCK and was also inhibited by
TPCK (Fig. 4, lanes 6 and 7). Similar results were obtained
with recombinant human lamin B (data not shown). We do not
have a definitive explanation for this difference in the cleavage
of recombinant and nuclear lamins. Despite the fact that the
lamin protease is a soluble cytoplasmic activity in S/M ex-
tracts, cleavage of endogenous nuclear lamins may also involve
an additional TLCK-sensitive nuclear factor.
DISCUSSION
The execution phase of apoptosis is mediated, at least in part,
by activation of ced3/ICE family proteinases (1, 28). One
substrate cleaved very early in apoptosis by these enzymes is
the nuclear enzyme PARP (12, 16). Here, we have studied a
second proteolytic event that is common to apoptosis in a
number of cell types: cleavage of the nuclear lamins into
discrete fragments. Like the PARP proteinase, the lamin
proteinase was inhibited by YVAD-cmk, an inhibitor of ICE-
like proteinases. However, the lamin proteinase differs from
the PARP proteinase, as shown by differences in the kinetics
with which these enzymes cleave their substrates and in the
relative sensitivity of these two activities to YVAD-cmk and
TLCK. Our experiments provide evidence for the involvement
of multiple ICE-like proteinases in a single apoptotic pathway.
This represents a fundamental difference from Caenorhabditis
elegans, where a single ICE-like proteinase (the product of the
ced-3 gene) has been identified (29, 30).
Although the identity of the lamin protease is unknown, one
can envision three possibilities. (i) The lamin proteinase might
be the so-called nuclear scaffold proteinase that cleaves lamins
A and C to produce a fragment with ATPase activity (31).
However, the nuclear scaffold proteinase is inhibited by a
specific chloromethylketone inhibitor, AAPF-cmk, by leupep-
tin, and by removal of Ca2+ (32), none of which inhibit the
lamin proteinase in our cell-free system (data not shown). (ii)
The lamin protease could be a TLCK-sensitive serine esterase
that is activated by the PARP proteinase or by a second
ICE-like enzyme as part of a proteinase cascade. This would
explain the preferential sensitivity of the lamin proteinase to
YVAD-cmk and would be consistent with the delayed kinetics
of lamin cleavage relative to PARP cleavage. However, the
resistance of the lamin protease to a variety of additional serine
esterase inhibitors is difficult to explain by this model. (iii) It
is possible that the lamin proteinase is itself an ICE family
member that is sensitive to both YVAD-cmk and TLCK. This
is consistent with the inhibitor studies described above, and
also with preliminary results indicating that a cloned human
ICE-like enzyme can cleave lamins in a cell-free system (A.T.,
E. Alnemri, T. Fernandes-Alnemri, G. Litwack, R.D.M.,
R.D.G., Y.A.L., G.G.P., S.H.K., and W.C.E., unpublished
work). CPP32, one candidate for the PARP proteinase (17),
does not cleave purified recombinant lamins in vitro.
The lamin proteinase appears to play an important role in
the later stages of apoptosis. When its activity is selectively
inhibited, the pathway of morphological changes is blocked at
the stage of chromatin condensation and collapse against the
nuclear rim. Subdivision of the characteristic condensed chro-
matin rim into individual domains and their subsequent con-
densation into discrete apoptotic bodies do not occur. This
phenotype is consistent with current understanding of the role
of lamins in nuclear architecture. The lamins bind to DNA in
general and to scaffold attachment regions in particular (33,
34). Thus, it has been proposed that the lamins play a major
functional role in the organization of the chromatin around the
nuclear periphery. Our observations suggest that lamin cleav-
age is required to disrupt this lamin-chromatin interaction,
thereby freeing the chromatin at the nuclear rim to be pack-
aged into multiple apoptotic bodies.
Finally, the present study has demonstrated that multiple
biochemical pathways operate in parallel during the execution
phase of apoptosis. We have specifically examined three
distinct activities: the PARP proteinase, the lamin proteinase,
and the fragmentation nuclease. We have found that both the
PARP proteinase and the fragmentation nuclease are fully
active when the lamin proteinase is inhibited by TLCK. Under
these conditions, the apoptotic pathway proceeds only part
way, and events are blocked at an early stage with the
chromatin collapsed against the nuclear rim. Thus the PARP
proteinase and the fragmentation nuclease acting alone or in
combination are insufficient to drive the final disassembly of
the nucleus into apoptotic bodies. Conversely, the combination
of the PARP and lamin proteinases is also not sufficient to
drive the apoptotic pathway. We show here that both enzymes
are fully active in the presence of EDTA (Fig. 2). We have
previously shown that nuclei exhibit no hint of chromatin
condensation or fragmentation nuclease activity under these
same conditions (15), possibly because of inactivation of the
domain nuclease by EDTA (35). What emerges from these
observations is a picture of nuclear apoptotic events in verte-
brate cells that begins with the activation of multiple ICE-like
proteinases and then ramifies into a number of pathways that
operate in parallel to effect the rapid disassembly of the entire
cell.
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